Tag : LungCancer

First-line lorlatinib shows 5-year benefits in Asian patients with ALK+ NSCLC: Post-hoc analysis from the CROWN trial
Lorlatinib, a third-generation, brain-penetrant anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, demonstrates potent antitumor activity in patients with ALK-positive (ALK+) non-small cell lung carcinoma (NSCLC) and is approved as a first-line treatment in many countries. This post-hoc analysis presents long-term outcomes in the Asian subgroup of the CROWN study, following a 5-year observation period.